Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Metastatic Collecting Duct Renal Cell Carcinoma
NCT03354884Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jan 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in collecting duct carcinoma (CDC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Jan 2018; status: completed.
02
Drugs
cabozantinib
03
Conditions
collecting duct carcinoma (CDC)
Beyond the preview
Go deeper on NCT03354884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03354884.